4/26
11:17 am
maze
What Makes Maze Therapeutics (MAZE) One of the Best Oversold Small-Cap Stocks to Buy [Yahoo! Finance]
Low
Report
What Makes Maze Therapeutics (MAZE) One of the Best Oversold Small-Cap Stocks to Buy [Yahoo! Finance]
4/22
12:09 am
maze
Maze Therapeutics Announces $150 Million Registered Offering
Low
Report
Maze Therapeutics Announces $150 Million Registered Offering
4/20
10:57 pm
maze
Truist Updates Maze Therapeutics, Inc. (MAZE) Model for Share Count and Warrant Impact [Yahoo! Finance]
Medium
Report
Truist Updates Maze Therapeutics, Inc. (MAZE) Model for Share Count and Warrant Impact [Yahoo! Finance]
4/18
01:00 am
maze
Medium
Report
4/14
09:11 am
maze
Maze Therapeutics (MAZE) was given a new $64.00 price target by Truist Financial Corporation.
Low
Report
Maze Therapeutics (MAZE) was given a new $64.00 price target by Truist Financial Corporation.
4/4
08:28 pm
maze
Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors. [Globe and Mail, The (Toronto, Canada)]
Low
Report
Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors. [Globe and Mail, The (Toronto, Canada)]
4/4
08:07 pm
maze
Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors. [Yahoo! Finance]
Low
Report
Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors. [Yahoo! Finance]
3/31
12:27 pm
maze
Maze Therapeutics (MAZE) had its price target raised by JPMorgan Chase & Co. from $52.00 to $58.00. They now have an "overweight" rating on the stock.
Low
Report
Maze Therapeutics (MAZE) had its price target raised by JPMorgan Chase & Co. from $52.00 to $58.00. They now have an "overweight" rating on the stock.
3/28
01:05 am
maze
Medium
Report
3/26
09:40 am
maze
MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Medium
Report
MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
3/25
01:51 pm
maze
Maze Therapeutics (MAZE) had its "buy" rating reaffirmed by BTIG Research. They now have a $46.00 price target on the stock.
Medium
Report
Maze Therapeutics (MAZE) had its "buy" rating reaffirmed by BTIG Research. They now have a $46.00 price target on the stock.
3/25
11:17 am
maze
Maze Therapeutics (MAZE) had its price target raised by HC Wainwright from $60.00 to $110.00. They now have a "buy" rating on the stock.
Medium
Report
Maze Therapeutics (MAZE) had its price target raised by HC Wainwright from $60.00 to $110.00. They now have a "buy" rating on the stock.
3/25
07:00 am
maze
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease
High
Report
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease
3/25
07:00 am
maze
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
High
Report
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
3/21
10:40 pm
maze
Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears [Yahoo! Finance]
Low
Report
Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears [Yahoo! Finance]
3/19
06:20 am
maze
Maze Therapeutics (MAZE) was upgraded by Truist Financial Corporation to "strong-buy".
Low
Report
Maze Therapeutics (MAZE) was upgraded by Truist Financial Corporation to "strong-buy".
3/17
07:03 pm
maze
Maze Therapeutics (MAZE) was given a new $68.00 price target by Truist Financial Corporation.
Medium
Report
Maze Therapeutics (MAZE) was given a new $68.00 price target by Truist Financial Corporation.
3/16
08:43 am
maze
Maze Therapeutics (MAZE) had its price target raised by Wedbush from $43.00 to $58.00. They now have an "outperform" rating on the stock.
Low
Report
Maze Therapeutics (MAZE) had its price target raised by Wedbush from $43.00 to $58.00. They now have an "outperform" rating on the stock.
3/13
06:18 am
maze
Maze Therapeutics (MAZE) was upgraded by Mizuho to "strong-buy".
Medium
Report
Maze Therapeutics (MAZE) was upgraded by Mizuho to "strong-buy".
3/10
08:03 am
maze
Maze Therapeutics (MAZE) is now covered by Mizuho. They set an "outperform" rating and a $97.00 price target on the stock.
High
Report
Maze Therapeutics (MAZE) is now covered by Mizuho. They set an "outperform" rating and a $97.00 price target on the stock.
3/9
08:03 am
maze
Maze Therapeutics (MAZE) had its "buy" rating reaffirmed by BTIG Research. They now have a $46.00 price target on the stock.
Low
Report
Maze Therapeutics (MAZE) had its "buy" rating reaffirmed by BTIG Research. They now have a $46.00 price target on the stock.
3/4
08:44 am
maze
Maze Therapeutics (MAZE) had its price target raised by Guggenheim from $46.00 to $58.00. They now have a "buy" rating on the stock.
Low
Report
Maze Therapeutics (MAZE) had its price target raised by Guggenheim from $46.00 to $58.00. They now have a "buy" rating on the stock.
2/25
07:00 am
maze
Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
Low
Report
Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
2/16
02:12 am
maze
Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge [Yahoo! Finance]
Low
Report
Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge [Yahoo! Finance]
2/14
07:51 pm
maze
Maze Therapeutics (MAZE) Valuation Check After Strong 1 Year Shareholder Return [Yahoo! Finance]
Low
Report
Maze Therapeutics (MAZE) Valuation Check After Strong 1 Year Shareholder Return [Yahoo! Finance]